Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicentre, Randomized, Double-blinded, Placebo-controlled, Parallel Group, Single-dose Design to Determine the Efficacy and Safety of Intravenous NA-1 in Subjects With Acute Ischemic Stroke Undergoing Endovascular Thrombectomy

Next Previous
Trial Profile

A Multicentre, Randomized, Double-blinded, Placebo-controlled, Parallel Group, Single-dose Design to Determine the Efficacy and Safety of Intravenous NA-1 in Subjects With Acute Ischemic Stroke Undergoing Endovascular Thrombectomy

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 03 Oct 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nerinetide (Primary)
  • Indications Stroke
  • Focus Registrational; Therapeutic Use
  • Acronyms ESCAPE-NA1
  • Sponsors NoNO

    • Most Recent Events

    • 23 Jan 2024 Results (n=77) of analysis assessing infarct evolution on MR-DWI after thrombectomy in patients included had MRI of sufficient quality published in the Neurology
    • 01 Sep 2023 Results assessing whether CTP modifies the effect of near-complete reperfusion on clinical outcomes, ie, whether poor clinical outcomes despite near-complete reperfusion can be partly or fully explained by CTP findings published in the American Journal of Neuroradiology
    • 12 Apr 2023 Results (n=1092) assessing the incidence of Infarct in a new territory, outcomes after Infarct in a new territory, and the impact of concurrent treatments with intravenous thrombolysis and nerinetide, published in the Stroke.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top